Aslan Pharmaceuticals Ltd.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
REGNRegeneron Pharmaceuticals, Inc. -0.99%570.922.7%$667.93m
ILMNIllumina, Inc. -0.30%319.503.5%$656.54m
AMGNAmgen, Inc. -1.34%228.001.3%$591.17m
ARRYArray BioPharma Inc. 2.42%39.4314.2%$514.29m
GILDGilead Sciences, Inc. -0.60%60.191.0%$504.00m
MRNAModerna, Inc. -1.98%69.900.0%$493.73m
VRTXVertex Pharmaceuticals, Inc. -2.00%210.251.9%$470.05m
IMMUImmunomedics, Inc. 0.09%87.8011.0%$388.12m
NVAXNovavax, Inc. -6.21%92.2596.5%$305.80m
ALXNAlexion Pharmaceuticals, Inc. -3.45%119.732.0%$287.47m
BIIBBiogen, Inc. -1.11%264.151.6%$254.74m
EXASEXACT Sciences Corp. -1.82%101.1420.7%$225.15m
BNTXBioNTech SE -6.09%88.600.0%$211.71m
SRNESorrento Therapeutics, Inc. -3.47%7.941.4%$186.02m
SGENSeagen Inc. 0.79%199.586.0%$171.42m

Company Profile

Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. Its pipeline includes varlitinib, ASLAN003, ASLAN004, and ASLAN002. The firm's portfolio focuses on validated growth pathways applied to new patient segments, novel immune checkpoints, and novel cancer metabolic pathways. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.